Lee / Zhu Mass Spectrometry in Drug Metabolism and Disposition

Basic Principles and Applications
1. Auflage 2011
ISBN: 978-0-470-93469-2
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: 0 - No protection

E-Book, Englisch, 800 Seiten, E-Book

Reihe: Wiley Series on Pharmaceutical Science

This book examines the background, industrial context, process, analytical methodology, and technology of metabolite identification. It emphasizes the applications of metabolite identification in drug research. While primarily a textbook, the book also functions as a comprehensive reference to those in the industry. The authors have worked closely together and combine complementary backgrounds to bring technical and cultural awareness to this very important endeavor while serving to address needs within academia and industry It also contains a variety of problem sets following specific sections in the text.

Autoren/Hrsg.

Lee, Mike S.

Zhu, Mingshe

Inhaltsverzeichnis

Foreword (Tom Baillie).
Preface (Mike Lee and Mingshe Zhu).
Contributors.
Part I. Basic Concepts of Drug Metabolism andDisposition.
1. Progression of Drug Metabolism (Ronald E. White).
2. Common Biotransformation Reactions (Bo Wen and Sidney D.Nelson).
3. Metabolic Activation of Organic Functional Groups Utilized inMedicinal Chemistry (Amit S. Kalgutkar).
4. Drug-Metabolizing Enzymes, Transporters, and Drug-DrugInteractions (Steven W. Louie and Magang Shou).
5. Experimental Models of Drug Metabolism and Disposition(Gang Luo, Chuang Lu, Xinxin Ding, and Donglu Zhang).
6. Principles of Pharmacokinetics: Predicting HumanPharmacokinetics in Drug Discovery (Takehito Yamamoto, AkihiroHisaka, and Hiroshi Suzuki).
7. Drug Metabolism Research as Integral Part of Drug Discoveryand Development Processes (W. Griffith Humphereys).
Part II. Mass Spectrometry in Drug Metabolism: Principles andCommon Practice.
8. Theory and Instrumentation of Mass Spectrometry(Gérard Hopfgartner).
9. Common Liquid Chromatography-Mass Spectrometry (LC-MS)Methodology for Metabolite Identification (Lin Xu, Lewis J.Klunk, and Chandra Prakash).
10. Mass Spectral Interpretation (Li-Kang Zhang and Birendra N.Pramanik).
11. Techniques to Facilitate the Performance of MassSpectrometry: Sample Preparation, Liquid Chromatography, andNon-Mass-Spectrometric Detection (Mark Hayward, Maria D.Bacolod, Qing Ping Han, Manuel Cajina, and Zack Zou).
Part III. Applications of New LC-MS Techniques in DrugMetabolism and Disposition.
12. Quantitative In Vitro ADME Assays Using LC-MS as a Part ofEarly Drug Metabolism Screening (Walter Korfmacher).
13. High-Resolution Mass Spectrometry and Drug MetaboliteIdentification (Russell J. Mortishire-Smith, Haiying Zhang, andKevin P. Bateman).
14. Distribution Studies of Drugs and Metabolites in Tissue byMass Spectrometric Imaging (Richard F. Reich, Daniel P.Magparangalan, Timothy J. Garrett, and Richard A. Yost).
15. Use of Triple Quadrupole-Linear Ion Trap Mass Spectrometryas a Single LC-MS Platform in Drug Metabolism and Pharmacokinetics(Wenying Jian, Ming Yao, Bo Wen, Elliott B. Jones, and MingsheZhu).
16. Quantitative Drug Metabolism with Accelerator MassSpectrometry (John S. Vogel, Peter Lohstroh, Brad Keck, andStephen R. Dueker).
17. Standard-Free Estimation of Metabolite Levels UsingNanospray Mass Spectrometry: Current Statutes and Future Directions(Jing-Tao Wu).
18. Profiling and Characterization of Herbal Medicine and ItsMetabolites Using LC-MS (Zeper Abliz, Ruiping Zhang, Ping Geng,Dongmei Dai, Jiuming He, and Jian Liu).
19. Liquid Chromatography Mass Spectrometry Bioanalysis ofProtein Therapeutics and Biomarkers in Biological Matrices(Fumin Li and Qin C. Ji).
20. Mass Spectrometry in the Analysis of DNA, Protein, Peptide,and Lipid Biomarkers of Oxidative Stress (Stacy L. Gelhaus andIan A. Blair).
21. LC-MS in Endogenous Metabolite Profiling and Small-MoleculeBiomarker Discovery (Michael D. Reily, Petia Shipkova, andSerhiy Hnatyshyn).
Appendix.
Index.

Über Autor(innen)

MIKE S. LEE, PhD, is President of Milestone DevelopmentServices. His recent work has involved the development of automatedorthogonal control systems for electrospray ionization. Formerly,Dr. Lee was director of analytical research and development atBristol-Myers Squibb (BMS) Pharmaceutical Research Institute wherehe led interdisciplinary teams that contributed to the Food andDrug Administration's approval of Buspar® and Serzone®,and the accelerated development and approval of Taxol®. Inaddition, he has authored over forty scientific papers and issuedpatents.
MINGSHE ZHU, PhD, is a drug metabolism researcher atBristol-Myers Squibb, where he leads a team that investigatesbiotransformation in new drug discovery and preclinical drugmetabolism and pharmacokinetics in development. His teams haveprovided key metabolism and disposition information for regulatoryapproval of Abilify® and NDA submission of Dapagliflozin. Dr.Zhu's research interests include LC/MS technology, optimization ofADME properties, metabolic activation, and regulatory drugmetabolism. He has been frequently invited to speak and teach shortcourses at conferences/workshops and has coauthored over sixtyresearch articles and one book.